Ozerbil 2006.

Study characteristics
Methods	Design: cross‐over Duration: 2 weeks Assessment: baseline and post‐intervention Country: Turkey
Participants	Pain condition: fibromyalgia Population: adult women aged 20‐60 with fibromyalgia Minimum pain intensity: no Inclusion criteria Aged 20‐60 Fibromyalgia according to ACR classification Exclusion criteria Current or past history of systemic illness, including cardiac, renal, haematologic, or hepatic disease Total participants randomised: 15 Age in years (mean, SD): NR Gender: 15/15 were female Pain duration in years (mean, SD): NR
Interventions	Amitriptyline 25 mg + placebo TCA + placebo Fixed dose Double‐dummy design Fluoxetine 20 mg + placebo SSRI + placebo Fixed dose Double‐dummy design
Outcomes	The study provided no useable data
Missing data methods	NR
Funding source	NR
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomised using randomisation tables
Allocation concealment (selection bias)	Unclear risk	Allocation procedure not specified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind, dummy dosing technique and identical tablets
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Researcher blinding ‐ not enough information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information regarding missing data or withdrawal given
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias identified